Vistagen Therapeutics, Inc.

Name: Vistagen Therapeutics, Inc. standardized financial statements, quarterly
Creator: Listed

VTGNNasdaqCIK 1411685HealthcareFiscal year ends Mar 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$1.5m, Q1 FY2027

Operating income−$13.3m, Q1 FY2027

Net income−$13.0m, Q1 FY2027

Vistagen Therapeutics, Inc., income statement, quarterly
Line item	Unit	Q2 FY20242023-09-30	Q3 FY20242023-12-31	Q4 FY20242024-03-31	Q1 FY20252024-06-30	Q2 FY20252024-09-30	Q3 FY20252024-12-31	Q4 FY20252025-03-31	Q1 FY20262025-06-30	Q2 FY20262025-09-30	Q3 FY20262025-12-31	Q4 FY20262026-03-31	Q1 FY20272026-06-30
Revenue	$m	0.3	0.4	0.2	0.1	0.2	0.2	(0.0)	0.2	0.3	0.3	0.5	1.5
Research and development	$m	3.9	4.5	7.4	7.6	10.2	11.3	10.2	11.7	15.9	14.2	13.1	10.9
Operating income	$m	(6.8)	(7.9)	(11.4)	(12.1)	(14.2)	(15.1)	(14.5)	(15.8)	(20.1)	(19.5)	(16.7)	(13.3)
Interest expense	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Income tax	$m	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	$m	(6.6)	(6.4)	(9.5)	(10.7)	(13.0)	(14.1)	(13.6)	(15.1)	(19.4)	(18.9)	(16.3)	(13.0)
Diluted EPS	$ per share	(0.66)	(0.22)	not reported	(0.35)	(0.42)	(0.46)	not reported	(0.47)	(0.54)	(0.45)	not reported	(0.30)
Basic EPS	$ per share	(0.66)	(0.22)	not reported	(0.35)	(0.42)	(0.46)	not reported	(0.47)	(0.54)	(0.45)	not reported	(0.30)

Balance sheet

Cash and equivalents$17.0m, Q1 FY2027

Shareholders' equity$24.5m, Q1 FY2027

Vistagen Therapeutics, Inc., balance sheet, quarterly
Line item	Unit	Q2 FY20242023-09-30	Q3 FY20242023-12-31	FY20242024-03-31	Q1 FY20252024-06-30	Q2 FY20252024-09-30	Q3 FY20252024-12-31	FY20252025-03-31	Q1 FY20262025-06-30	Q2 FY20262025-09-30	Q3 FY20262025-12-31	FY20262026-03-31	Q1 FY20272026-06-30
Cash and equivalents	$m	37.6	127	119	103	84.2	74.7	67.1	49.0	62.8	47.4	30.8	17.0
Current assets	$m	39.1	128	121	111	99.9	89.9	82.1	66.7	78.9	63.2	46.9	34.3
Total assets	$m	42.2	131	124	114	102	92.3	84.3	68.9	80.9	65.1	48.6	35.7
Current liabilities	$m	2.9	4.2	5.1	6.2	7.5	9.6	12.6	11.2	13.6	13.5	12.8	11.2
Total liabilities	$m	6.6	7.8	9.4	8.7	9.5	11.2	14.0	12.2	14.6	14.1	13.0	11.3
Long-term debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Current portion of debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Short-term borrowings	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	35.6	123	114	105	93.0	81.1	70.4	56.8	66.3	50.9	35.5	24.5

Cash flow

Operating cash flow−$14.7m, Q1 FY2027

Vistagen Therapeutics, Inc., cash flow, quarterly
Line item	Unit	Q2 FY20242023-09-30	Q3 FY20242023-12-31	Q4 FY20242024-03-31	Q1 FY20252024-06-30	Q2 FY20252024-09-30	Q3 FY20252024-12-31	Q4 FY20252025-03-31	Q1 FY20262025-06-30	Q2 FY20262025-09-30	Q3 FY20262025-12-31	Q4 FY20262026-03-31	Q1 FY20272026-06-30
Operating cash flow	$m	(6.2)	(4.7)	(7.0)	(10.9)	(10.9)	(10.3)	(10.1)	(18.8)	(13.8)	(17.6)	(16.2)	(14.7)
Capital expenditure	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)42.98m, Q1 FY2027

Vistagen Therapeutics, Inc., shares, quarterly
Line item	Unit	Q2 FY20162015-09-30	Q3 FY20162015-12-31	Q1 FY20242023-06-30	Q2 FY20242023-09-30	Q3 FY20242023-12-31	Q1 FY20252024-06-30	Q2 FY20252024-09-30	Q3 FY20252024-12-31	Q1 FY20262025-06-30	Q2 FY20262025-09-30	Q3 FY20262025-12-31	Q1 FY20272026-06-30
Diluted shares (weighted)	m shares	1.6	1.8	7.3	10.0	29.4	30.6	30.6	30.7	31.9	35.7	42.2	43.0

Shares outstanding: 44.38m at Aug 10, 2026, from the cover of the 10-Q filed Aug 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. Listed shows no prices and gives no investment advice.